Integral Diagnostics (Integral Diagnostics) EBITDA Margin % : -13.62% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Integral Diagnostics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Integral Diagnostics's EBITDA for the six months ended in Dec. 2023 was $-21.1 Mil. Integral Diagnostics's Revenue for the six months ended in Dec. 2023 was $154.8 Mil. Therefore, Integral Diagnostics's EBITDA margin for the quarter that ended in Dec. 2023 was -13.62%.

Integral Diagnostics EBITDA Margin % Historical Data

The historical data trend for Integral Diagnostics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integral Diagnostics EBITDA Margin % Chart

Integral Diagnostics Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EBITDA Margin %

Get a 7-Day Free Trial

21.79

25.36

25.53

19.44

21.01

Integral Diagnostics Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial												20.89	17.98	22.44	19.64	-13.62

Competitive Comparison of Integral Diagnostics's EBITDA Margin %

For the Diagnostics & Research subindustry, Integral Diagnostics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Integral Diagnostics's EBITDA Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Integral Diagnostics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Integral Diagnostics's EBITDA Margin % falls into.

Integral Diagnostics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Integral Diagnostics's EBITDA Margin % for the fiscal year that ended in Jun. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	62.07	/	295.368
	=	21.01 %

Integral Diagnostics's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-21.087	/	154.788
	=	-13.62 %

Integral Diagnostics (OTCPK:ITGDF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Integral Diagnostics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Integral Diagnostics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Integral Diagnostics (Integral Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Integral Diagnostics Ltd (OTCPK:ITGDF) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

IDX:Australia

Address

45 William Street, Suite 9.02, Level 9, Melbourne, VIC, AUS, 3000

Website

http://www.integraldiagnostics.com.au

Integral Diagnostics is Australia's fourth-largest diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.